An interventional study of mixed nuts. Group A and mixed nuts. Group B in Depression Disorder, Anxiety and Mental Health, sponsored by University of Castilla-La Mancha. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by University of Castilla-La Mancha · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 225 studies in Depression with a site in Spain — 46 open to participants now, 58 under way, 7 of them phase 3. Depression · Spain.
Among the 225 studies in Depression with a site in Spain, this one is the 89th largest by planned enrollment of the 189 interventional ones that give a count, is one of 21 that started in 2025, is one of 153 with no phase, reaches primary completion later than 33 of the 57 other live ones, and was the 203rd registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →46 of the 225 studies in Depression with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Australia and 12 more countries
Ages 18–75
University of Seville · Sites in Spain
Ages 18+ · Women only · Healthy volunteers
University of Seville · Sites in Spain
Ages 18+ · Healthy volunteers
Fundació Sant Joan de Déu · Sites in Spain
Ages 18+
University of the Basque Country (UPV/EHU) · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 24 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
225 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 18 · Phase 4 6
First in 2002; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 135 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 123 across the 189 interventional studies, 303 across the 36 observational. Of the 130 that completed or were terminated, 17 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 225 have an industry lead sponsor. The 10 most frequent:
University of Castilla-La Mancha is the lead sponsor of 108 studies on the registry; 26 are open to participants now.
University of Castilla-La Mancha has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
9 of the studies in Depression with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT07925723Universidad Miguel Hernandez de ElcheALAS PROPIAS: Music Therapy for Women Experiencing Machista Violence in Intimate Partner Relationships | 2026-11-30 |
| NCT07292610University of Castilla-La ManchaImpact of Nut Consumption on Mental Health in Young Adults | 2026-12 |
| NCT05289258Universidad de CórdobaUnified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments | 2026-12-30 |
| NCT04084795Parc de Salut MarAugmentation of EMDR With tDCS in the Treatment of Fibromyalgia | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 225 studies in Depression with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Nuts have a high nutrient density, and numerous studies have reported their cardiometabolic benefits. Although observational studies in adults have indicated a potential link between nut consumption and improved mental health, there is still insufficient evidence from experimental studies to draw firm conclusions about this association.
Nuts are widely recognized for their high nutrient density and their multiple reported cardiometabolic benefits. They are rich in monounsaturated (MUFAs) and polyunsaturated (PUFAs) fatty acids (including omega-3 alpha-linolenic acid and omega-6 linoleic acid) as well as antioxidants and compounds with anti inflammatory properties. Observational studies in adults have suggested a potential association between nut consumption and improved mental health, including a reduced risk of depression and enhanced mood. However, evidence from experimental studies remains limited and often inconclusive.
Early adulthood (ages 18-24) represents a critical developmental period marked by substantial physical, psychological, and social changes, and it is also a stage during which mental health problems commonly emerge.
The Nuts4Brain-RCT will investigate the impact of a 6-month mixed-nut intervention on mental health symptoms, cognitive functioning, sleep quality, overall well-being, health-related quality of life, and biochemical mediators of brain function and mental health in young adults.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
This study's planned enrollment of 135 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Browse Depression studies →University of Castilla-La Mancha is the lead sponsor of 108 studies on the registry; 26 are open to participants now.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all the following criteria to be considered eligible for selection and randomization:
Inclusion Criteria:
Participants will be excluded from the study if they have any of the following conditions, based on self-reported information:
Exclusion Criteria:
Usual dietary habits.
Other: control group
Nut consumption (walnuts, almonds, pistachios, and hazelnuts mix).
Dietary Supplement: mixed nuts. Group A
Nut consumption (walnuts, almonds, pistachios, and hazelnuts mix).
Dietary Supplement: mixed nuts. Group B
Participants will be instructed to consume a single daily dose of nuts (30 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 moths). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer. Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected
Participants will be instructed to consume two daily doses of nuts (60 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 months). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer.Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected
Participants will be instructed to maintain their regular diet without any specific dietary instructions or intervention.
Depression
Changes in symptoms of depression assessed with the Beck Depression Inventory Version II (BDI-II). Each of the 21 items includes four statements of increasing severity, and a total score (ranging from 0 to 63) is calculated, with higher scores indicating more severe depression.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Anxiety
Changes in symptoms of anxiety assessed with The Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of seven questions asking individuals to rate the frequency and severity of specific anxiety symptoms over the past two weeks.The total score ranges from 0 to 21, calculated by summing the scores of all seven items. A score of 10 or greater is considered a reasonable cut-off point for identifying possible cases of GAD that may require further clinical evaluation
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Stress
Changes in symptoms of stress assessed with The Perceived Stress Scale (PSS-10). The PSS-10 is a widely used, 10-item self-report questionnaire that measures an individual's perception of stress over the past month. Scoring involves reverse-scoring four positive items and summing all 10. Total scores range from 0 to 40, with higher scores indicating more perceived stress. Scores can be interpreted generally as low (0-13), moderate (14-26), or high (27-40) stress.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Episodic memory
The Picture Sequence Memory Test assesses episodic memory by requiring participants to encode and recall the temporal order of a sequence of visually presented everyday events. After presentation, individuals are asked to reconstruct the sequence in its original order, allowing evaluation of visual episodic memory and learning across trials. Test time: 7 minutes. This test is one of the measures included in the NIH Toolbox Cognition Battery, which is administered on an iPad by qualified personnel.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Working memory
The List Sorting Working Memory Test (LSWM), part of the NIH Toolbox Cognition Batery, assesses working memory by having individuals recall and sequence visually and auditorily presented stimuli (like animal/food pictures) in size order (smallest to largest). Test time: 7 minutes.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Cognitive flexibility
The Dimensional Change Card Sort Test is a standardized measure of cognitive flexibility. Participants are required to sort cards according to different rules (e.g., color or shape) and to adapt their responses when the sorting dimension changes. Test time: 5 minutes. This test is one of the tests that will be determined using the NIH Toolbox Cognition Battery, which will be administered on an iPad by qualified personnel.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Processing speed
The Pattern Comparison Processing Speed Test is a standardized measure of processing speed. Participants are asked to quickly determine whether two visual patterns are the same or different, emphasizing speed and accuracy of visual perception and decision-making. Test Time: 4 minutes. This test is one of the tests that will be determined using the NIH Toolbox Cognition Battery, which will be administered on an iPad by qualified personnel.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Inhibitory control and attention
The Flanker Inhibitory Control and Attention Test is a standardized measure of inhibitory control and selective attention, core components of executive function. Participants are required to focus on a central target stimulus while inhibiting interference from surrounding distractor stimuli. Performance reflects the ability to maintain attention, suppress competing responses, and resolve cognitive conflict. Test Time: 3 minutes. This test is one of the tests that will be determined using the NIH Toolbox Cognition Battery, which will be administered on an iPad by qualified personnel.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Brain Derived Neurotrophic Factor
Changes in blood concentration of brain-derived neurotrophic factor (BDNF), a biochemical mediator of brain functioning
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Sleep quality
Changes in quality of sleep assessed with the Pittsburgh Sleep Quality Index (PSQI). The PSQI consists of 19 individual self-rated questions (and 5 optional questions for a roommate/bed partner) that are grouped into seven component scores. Each of the seven components is scored on a scale of 0 to 3, where 0 indicates no difficulty and 3 indicates severe difficulty. The scores of these components are summed to produce a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Health-related quality of life (HRQL)
Changes in health-related quality of life assessed with the SF12 questionnaire. It consists of 12 questions that cover the same eight health domains as the longer SF-36: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. The 12 items are used to create two main summary measures through a complex, norm-based scoring algorithm: Physical Component Summary (PCS): A single score representing physical health status. Mental Component Summary (MCS): A single score representing mental and emotional health status. Interpretation of Scores: Scores for both PCS and MCS typically range from 0 to 100, where higher scores indicate better health and functioning.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Inflammatory biomarkers
Changes in blood inflammatory markers (e.g. hs-CRP) to examine underlying mechanisms
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Concentration of vitamins and minerals
Changes in blood concentration of specific vitamins and minerals (e.g., vitamins B9, B12, D, iron, and magnesium) to examine underlying mechanisms
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Body image
Changes in body image perception using The Standard Figural Stimuli (SFS). Measurement Purpose: Perceived Body Image: The figure the individual selects as most representative of their current body size. Ideal Body Image: The figure the individual would like to have. Body Dissatisfaction: The discrepancy between the perceived image and the ideal image. A larger difference indicates greater body dissatisfaction.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Screen time
Screen time will be assessed using an ad hoc questionnaire that records the number of hours of leisure time participants spend watching television, using a mobile phone, using a computer for work-related purposes, or engaging with other electronic devices, both on weekdays and during weekends.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Social media addiction
Changes in social media addiction through Social Network Addiction Questionnaire, 6-item version (ARS-6). The scale typically consists of 6 items, with one item representing each of the six components of addiction. Response Scale: Responses are typically given on a 5-point Likert scale (e.g., from 1 = Not at all to 5 = Always). Scoring: Item responses are summed to obtain a total score, ranging from 6 to 30. Higher scores indicate a greater risk or severity of social media addiction.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Sociodemographic
Sociodemographic information such as age, sex, date of birth, country of origin, marital status, housing type, medication use, and family history of mental or cardiovascular disorders.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Drugs consumption
Changes in drugs consumption assessed with the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). The ASSIST generates substance-specific risk scores that categorize use into low, moderate, or high-risk categories. Higher scores indicate a greater risk of substance-related health and social problems, guiding the type of intervention needed (e.g., brief intervention or referral to specialist treatment).
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Adherence to the Mediterranean Diet
Changes in adherence to the mediterranean diet assessed with the MEDAS questionnaire. Scoring: Each item is scored with 1 point if the criteria for adherence to the Mediterranean diet are met, and 0 points if they are not. The total score ranges from 0 to 14 points. Higher scores indicate greater adherence to the Mediterranean diet. A common cut-off point of ≥9 is often used to define good adherence to the diet.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Resilience
Changes in resilience assessed with the Connor-Davidson Resilience Scale (CD-RISC 10). Each item is rated on a 5-point Likert scale ranging from 0 (not true at all) to 4 (true nearly all the time). The total score is calculated by summing the values of all 10 items. Total scores range from 0 to 40. Higher scores on the CD-RISC 10 indicate greater resilience and a better ability to cope with adversity and bounce back from difficult experiences.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Risk of eating disorders
The SCOFF questionnaire (an acronym derived from the initials of its English questions: Sick, Control, One stone, Fat, Food) is a brief and simple, five-question screening tool designed to detect the possible presence of eating disorders (EDs), such as anorexia nervosa and bulimia nervosa. The total score can range from 0 to 5. A score of two or more points is considered a positive screening result and suggests a suspicion of an ED that requires a detailed formal clinical assessment.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Weight
Weight in kilograms will be assessed twice using a calibrated digital scale (Scale Seca® 861) with participants barefoot and in light weight clothing.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Height
Height will be measured twice with a stadiometer (Wall stadiometer Seca® 222), with participants standing upright, barefoot, and with the sagittal midline aligned to the wall.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Body Mass Index (BMI)
BMI will be calculated as weight divided by height squared (kg/m2).
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Body fat percentage
Body fat percentage will be assessed twice using the bioimpedance analysis system under standardized conditions (morning, fasting, post-void, after 15 minutes rest, barefoot, with controlled temperature and humidity).
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Blood pressure
Blood pressure will be measured using an automated device (OMRON® M5-I (Omron Healthcare UK Ltd.)). Systolic and diastolic blood pressure will be assessed twice, with a 5-minute interval between measurements. Participants will be seated in a quiet environment, with the right arm semi-flexed at heart level.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Muscular strenght
Measured through handgrip strength using a calibrated dynamometer (Digital dynamometer TKK 5401 Grip-D (Takey®, Tokyo, Japan), and standing long jump for lower body strength. Handgrip: Kilograms (kg). Horizontal jump: Centimeters (cm).
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Phisical activity
Changes in phisical activity assessed with the The International Physical Activity Questionnaire (IPAQ). The data collected with the IPAQ can be reported as a continuous measure (estimation of total energy expenditure in MET-minutes per week) or categorically (classifying individuals into low, moderate, or high physical activity levels): Continuous Score: Total energy expenditure is calculated using specific formulas that assign MET (metabolic equivalent) values to each activity type (walking=3.3 METs, moderate=4.0 METs, vigorous=8.0 METs). Categorical Score: Participants are classified into three levels of physical activity based on predefined criteria related to the duration, frequency, and intensity of activities.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Lipid profile
Changes in blood lipid profile (Cholesterol (Total, HDL-c, LDL-c), triglycerides)) to examine underlying mechanisms.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Glucose levels
Changes in blood glucose levels to examine underlying mechanisms.
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Hemoglobin A1c (HbA1c)
Changes in blood HbA1c levels to examine underlying mechanisms.
Time frame: Day 0", "Month 3", "Month 6", "Month 12"
Adherence verification
Adherence to nut consumption intervention measured by blood levels of vitamin E
Time frame: "Day 0", "Month 3", "Month 6", "Month 12"
Plan to share: Yes — The data generated in this project will be publicly shared through Zenodo an open-access repository compliant with FAIR (Findable, Accessible, Interoperable, and Reusable) principles.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: These data will remain accessible for a minimum period of five years.
Access criteria: All data will be securely stored under the responsibility of the project's Principal Investigator, Arthur Eumann Mesas, ensuring compliance with institutional and ethical data protection requirements.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 13 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Castilla-La Mancha →